Merck & Co., Inc. MRK

Set alert

Price alert · MRK

All alert types
148.36 USD -1.16 -0.78%

At close · Nov 2

148.36 0.00 0.00%

After hours · Nov 2, 4:02 PM ET

Bid
148.45 × 400
Ask
148.46 × 100
147.12 Day range 150.25
82.01 52-week range 156.92
YTD
+40.95%
1 year
+72.55%
Open
148.82
Prev close
149.52
Mkt cap
366.03B
Vol
9.10M
Avg vol
10.36M
EPS
0.99
P/E
149.86
Div yield
2.27%
More statistics
Low
147.12
High
150.25
Forward P/E
16.34
Beta
0.12
Short ratio
2.68
Inst. own
82.88%
Dividend
3.40
Ex-div date
Sep 14, 2026
Earnings
Feb 2, 2027
50-d avg
146.86
200-d avg
126.71
1y target
159.91

5Y chart

Chart tools
Interval

Events in this range
  • Dec 14, 2021Dividend: 0.69
  • Mar 14, 2022Dividend: 0.69
  • Jun 14, 2022Dividend: 0.69
  • Sep 14, 2022Dividend: 0.69
  • Sep 15, 2022Dividend: 0.69
  • Dec 14, 2022Dividend: 0.73
  • Jan 9, 2023Dividend: 0.73
  • Mar 14, 2023Dividend: 0.73
  • Jun 14, 2023Dividend: 0.73
  • Sep 14, 2023Dividend: 0.73
  • Dec 14, 2023Dividend: 0.77
  • Mar 14, 2024Dividend: 0.77
  • Jun 17, 2024Dividend: 0.77
  • Sep 16, 2024Dividend: 0.77
  • Dec 16, 2024Dividend: 0.81
  • Mar 17, 2025Dividend: 0.81
  • Jun 16, 2025Dividend: 0.81
  • Sep 15, 2025Dividend: 0.81
  • Oct 30, 2025Earnings: 2.58; estimate 2.36; surprise 9.32%
  • Dec 15, 2025Dividend: 0.85
  • Feb 3, 2026Earnings: 2.04; estimate 2.01; surprise 1.49%
  • Mar 16, 2026Dividend: 0.85
  • Apr 30, 2026Earnings: -1.28; estimate -1.47; surprise 12.93%
  • Jun 15, 2026Dividend: 0.85
  • Aug 4, 2026Earnings: -0.13; estimate -0.27049; surprise 51.94%
  • Sep 15, 2026Dividend: 0.85
  • Oct 12, 2026Rating: Citigroup · Neutral → Neutral
  • Oct 26, 2026Rating: Barclays · Overweight → Overweight
  • Oct 29, 2026Earnings: 2.49; estimate 2.09; surprise 19.14%
  • Oct 30, 2026Rating: Guggenheim · Buy → Buy
  • Oct 30, 2026Rating: RBC Capital · Sector Perform → Sector Perform
  • Oct 30, 2026Rating: JP Morgan · Overweight → Overweight
  • Nov 2, 2026Rating: Cantor Fitzgerald · Neutral → Neutral
Signals (82)
NameDateAgo
SMA: BullishOct 26, 20261 week ago
MACD: Sell SignalOct 19, 20262 weeks ago
SMA: BearishOct 12, 20263 weeks ago
RSI: OverboughtAug 31, 20262 months ago
RSI: OverboughtAug 17, 20262 months ago
MACD: Buy SignalJun 29, 20264 months ago
SMA: BullishJun 22, 20264 months ago
SMA: BearishJun 15, 20264 months ago
SMA: BullishMay 18, 20265 months ago
SMA: BearishApr 13, 20266 months ago
SMA: BullishMar 23, 20267 months ago
MACD: Sell SignalMar 23, 20267 months ago
SMA: BearishMar 9, 20267 months ago
RSI: OverboughtFeb 2, 20269 months ago
RSI: OverboughtJan 5, 202610 months ago
SMA: BullishSep 29, 20251 year ago
SMA: BullishSep 29, 20251 year ago
SMA: BearishSep 8, 20251 year ago
SMA: BearishSep 8, 20251 year ago
SMA: BullishAug 11, 20251 year ago
SMA: BullishAug 11, 20251 year ago
SMA: BearishJul 28, 20251 year ago
SMA: BullishJun 30, 20251 year ago
SMA: BearishJun 23, 20251 year ago
SMA: BullishJun 9, 20251 year ago
MACD: Buy SignalJun 9, 20251 year ago
RSI: OversoldApr 7, 20251 year ago
MACD: Sell SignalMar 31, 20251 year ago
SMA: BearishMar 24, 20251 year ago
SMA: BullishMar 3, 20251 year ago
MACD: Buy SignalMar 3, 20251 year ago
MACD: Sell SignalFeb 3, 20251 year ago
RSI: OversoldFeb 3, 20251 year ago
MACD: Buy SignalJan 27, 20251 year ago
RSI: OversoldNov 11, 20241 year ago
RSI: OversoldOct 21, 20242 years ago
SMA: BearishJul 22, 20242 years ago
SMA: BearishJun 24, 20242 years ago
SMA: BullishJun 3, 20242 years ago
SMA: BearishMay 27, 20242 years ago
MACD: Sell SignalMay 20, 20242 years ago
MACD: Buy SignalMay 13, 20242 years ago
MACD: Sell SignalApr 29, 20242 years ago
SMA: BullishApr 22, 20242 years ago
SMA: BearishApr 8, 20242 years ago
SMA: BullishMar 25, 20242 years ago
RSI: OverboughtMar 25, 20242 years ago
SMA: BearishMar 4, 20242 years ago
RSI: OverboughtJan 1, 20242 years ago
SMA: BullishDec 18, 20232 years ago
MACD: Buy SignalDec 11, 20232 years ago
SMA: BullishNov 27, 20232 years ago
SMA: BearishSep 11, 20233 years ago
SMA: BullishAug 21, 20233 years ago
SMA: BearishJul 3, 20233 years ago
SMA: BearishJul 3, 20233 years ago
SMA: BullishJun 19, 20233 years ago
SMA: BullishJun 19, 20233 years ago
SMA: BearishJun 12, 20233 years ago
SMA: BearishMay 22, 20233 years ago
MACD: Sell SignalMay 22, 20233 years ago
MACD: Buy SignalApr 17, 20233 years ago
SMA: BullishApr 3, 20233 years ago
SMA: BearishFeb 27, 20233 years ago
SMA: BullishFeb 20, 20233 years ago
MACD: Sell SignalJan 30, 20233 years ago
SMA: BearishJan 16, 20233 years ago
RSI: OverboughtNov 21, 20223 years ago
MACD: Buy SignalOct 17, 20224 years ago
SMA: BullishOct 10, 20224 years ago
SMA: BullishOct 10, 20224 years ago
SMA: BearishSep 19, 20224 years ago
SMA: BullishSep 5, 20224 years ago
SMA: BearishAug 29, 20224 years ago
SMA: BearishAug 22, 20224 years ago
SMA: BullishAug 8, 20224 years ago
MACD: Sell SignalJul 25, 20224 years ago
SMA: BearishJul 18, 20224 years ago
SMA: BullishJun 20, 20224 years ago
SMA: BearishJun 6, 20224 years ago
SMA: BullishMar 14, 20224 years ago
SMA: BearishFeb 7, 20224 years ago

Key statistics

Market cap
366.35B
Enterprise value
415.71B
Trailing P/E
149.99
Forward P/E
16.34
PEG ratio
2.82
Price / sales
5.44
Price / book
8.74
EPS (TTM)
0.99
Beta
0.12
Dividend yield
2.27%
Payout ratio
266.67%
Profit margin
3.64%
Revenue (TTM)
67.38B
Revenue growth
4.70%
Free cash flow
0
Total cash
7.14B
Total debt
53.91B
Return on equity
0.00%
Shares outstanding
2.47B
Short % of float
1.09%
50-day average
146.86
200-day average
126.71

Analyst view

Consensus: buy

Buy
Price target (mean) 159.91 +7.8% upside
Target (low)
105.00
Target (mean)
159.91
Target (high)
186.00
Ratings (0m) 28 19 buy · 9 hold · 0 sell
  • Strong buy5
  • Buy14
  • Hold9
  • Sell0
  • Strong sell0

Next earnings

Feb 2, 2027

Expected Feb 2, 2027. Consensus EPS estimate 1.79.

Earnings history

Financials — quick view

All financials
MRK Revenue — quarterly 16.61B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRK Net income — quarterly -1.33B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRK EPS — quarterly -0.54
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MRK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 2, 2027Dec 30, 20261.79———
Oct 29, 2026Sep 30, 20262.092.49+0.40+19.14%
Aug 4, 2026Jun 30, 2026-0.27049-0.13+0.14+51.94%
Apr 30, 2026Mar 31, 2026-1.47-1.28+0.19+12.93%
Feb 3, 2026Dec 31, 20252.012.04+0.03+1.49%
Oct 30, 2025Sep 30, 20252.362.58+0.22+9.32%

Upgrades / downgrades

MRK analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026Cantor FitzgeraldmainNeutralNeutral
Oct 30, 2026JP MorganmainOverweightOverweight
Oct 30, 2026RBC CapitalmainSector PerformSector Perform
Oct 30, 2026GuggenheimmainBuyBuy
Oct 26, 2026BarclaysmainOverweightOverweight
Oct 12, 2026CitigroupmainNeutralNeutral

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
merck.com

News

Your note

Sign in to keep a note on MRK — it syncs with the Stock Master app.

Insider holders

MRK insider holders
InsiderRelationLatest transactionDateShares held
CHATTOPADHYAY SANATOfficerConversion of Exercise of derivative securityApr 28, 2026200,675
DAVIS ROBERT MChief Executive OfficerConversion of Exercise of derivative securityApr 28, 2026450,351
DELUCA RICHARD ROBERT JR.OfficerSaleAug 11, 2026110,167
GUINDO CHIRFIOfficerSaleAug 12, 202636,613
LI DEAN YOfficerConversion of Exercise of derivative securityApr 28, 202694,431
LITCHFIELD CAROLINEChief Financial OfficerConversion of Exercise of derivative securityApr 28, 202692,300

Institution ownership

MRK institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.20%226,999,83733.71BJun 29, 2026
Vanguard Capital Management LLC6.54%161,323,17423.95BJun 29, 2026
State Street Corporation4.88%120,413,25617.88BJun 29, 2026
Wellington Management Group, LLP3.50%86,249,28312.81BJun 29, 2026
Vanguard Portfolio Management LLC2.75%67,738,96910.06BJun 29, 2026
Geode Capital Management, LLC2.46%60,744,2149.02BJun 29, 2026

Fund ownership

MRK fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%78,411,37411.64BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%63,996,8849.50BJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF1.47%36,188,6065.37BAug 30, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%32,874,3674.88BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%32,060,5434.76BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%30,514,3124.53BSep 29, 2026